Kestrel Therapeutics
PrivateLast Round
Corporate Funding
Apr 28, 2026
Total Funding Raised
$48M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kestrel Therapeutics is a biotechnology company that develops small-molecule inhibitors targeting mutant KRAS proteins for the treatment of intractable cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kestrel Therapeutics Comparables
Compare Kestrel Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Quanta Therapeutics | 85% | |
| Jacobio Pharmaceuticals Group Co Ltd | 80% | |
| Revolution Medicines | 79% |
Kestrel Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Apr 28, 2026 | ||||
| VC Round | Aug 12, 2025 | ||||
| Convertible Debt | Feb 21, 2025 | ||||
| Series A | Dec 1, 2021 |
Kestrel Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series A |
| Cormorant Asset Management | Series A |
| Santé Ventures | VC Round, Series A |
| Pfizer | Series A |
| Cormorant Asset Management | Series A |
| Pfizer Ventures | VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
AbbVie led the corporate funding round.
- Aug 12, 2025
$5M raised from Pfizer Ventures and Santé Ventures.
Kestrel Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Kestrel Therapeutics's valuation, stock price, and market status.
Is Kestrel Therapeutics a public or private company?
Kestrel Therapeutics is a private company.
What is the current stock price of Kestrel Therapeutics?
Kestrel Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Kestrel Therapeutics worth (valuation)?
Valuation information for Kestrel Therapeutics is not publicly available.
Can I buy Kestrel Therapeutics stock?
Kestrel Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Kestrel Therapeutics's last funding round?
Kestrel Therapeutics's most recent funding round was VC Round on August 11, 2025.
Who are the main investors in Kestrel Therapeutics?
Key investors in Kestrel Therapeutics include S32, Pfizer, Cormorant Asset Management.
Will Kestrel Therapeutics IPO soon?
No public IPO plans have been announced for Kestrel Therapeutics.
How can I track Kestrel Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Kestrel Therapeutics's secondary market activity and sign up for updates.